Becaris
Browse

Supplementary materials: Digital variance angiography in patients undergoing lower limb arterial recanalization: cost–effectiveness analysis within the English healthcare setting

Download (21.3 kB)
dataset
posted on 2024-03-22, 12:56 authored by Amir Ansaripour, Eoin Moloney, Michael Branagan-Harris, Lorenzo Patrone, Mehdi Javanbakht

These are peer-reviewed supplementary materials for the article 'Supplementary materials: Digital variance angiography in patients undergoing lower limb arterial recanalization: cost–effectiveness analysis within the English healthcare setting' published in the Journal of Comparative Effectiveness Research.

  • Supplementary equation

Aim: Digital variance angiography (DVA) is a recently developed image processing method capable of improving image quality compared with the traditionally used digital subtraction angiography (DSA),among patients undergoing lower limb x-ray angiography. This study aims to explore the potential cost–effectiveness of DVA from an English National Health Service perspective. Materials & methods: A two-part economic model, consisting of a decision tree and a Markov model, was developed to consider the costs and health outcomes associated with the use of DVA as part of current practice imaging, compared with x-ray angiography using standard DSA. The model explored the impact of DVA on the development of acute kidney injury (AKI), chronic kidney disease and radiation-induced cancer over a lifetime horizon. Both deterministic and probabilistic analyses were performed to assess the cost per quality-adjusted life-year (QALY). Results: Base-case results indicate that DVA results in cost savings of £309 per patient, with QALYs also improving (+0.025) over a lifetime. As shown in sensitivity analysis, a key driver of model results is the relative risk (RR) reduction of contrast-associated acute kidney injury associated with use of DVA. The intervention also decreases the risk of carcinoma over a lifetime. Scenario analyses show that cost savings range from £310 to £553, with QALY gains ranging from 0.048 to 0.109 per patient. Conclusion: The use of DVA could result in a decrease in costs and an increase in QALYs over a lifetime, compared with existing imaging practice. The potential for this technology to offer an economically viable alternative to existing image processing methods, through a reduction in contrast media volume and radiation exposure, has been demonstrated.

Funding

This report is research funded by Kinepict Health Ltd in the framework of the European Union’s Horizon 2020 EIC Accelerator program (968430 KMIT-ACC).

History

Usage metrics

    Becaris

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC